Skip to Content
Merck
CN

C002

(±)-Quinuclidinyl benzilate

powder

Synonym(s):

(±)-QNB, (±)-Quinuclidinyl α-hydroxydiphenylacetate

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C21H23NO3
CAS Number:
6581-06-2
Molecular Weight:
337.41
NACRES:
NA.77
PubChem Substance ID:
329774757
UNSPSC Code:
12352200
MDL number:
MFCD00055094
Form:
powder
Quality level:
100

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI

1S/C21H23NO3/c23-20(25-19-15-22-13-11-16(19)12-14-22)21(24,17-7-3-1-4-8-17)18-9-5-2-6-10-18/h1-10,16,19,24H,11-15H2

SMILES string

OC(C(=O)OC1CN2CCC1CC2)(c3ccccc3)c4ccccc4

InChI key

HGMITUYOCPPQLE-UHFFFAOYSA-N

form

powder

color

white

solubility

chloroform: soluble (but decomposes within 24 hrs), methanol: stable (for up to two weeks at -20°C.)

εmax

13,500 at 207.4 nm in methanol

storage temp.

2-8°C

Quality Level

100

Biochem/physiol Actions

Nonselective muscarinic acetylcholine receptor antagonist.

Features and Benefits

This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Acetylcholine Receptors (Muscarinic) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

pictograms

Skull and crossbones
GHS06

signalword

Danger

hcodes

H300

Hazard Classifications

Acute Tox. 2 Oral

Storage Class

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

Regulatory Information

监管及禁止进口产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
021M4621V
073K4608

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Diego Muñoz-Torrero et al.
Neuro-degenerative diseases, 10(1-4), 96-99 (2012-01-13)
Multifactorial diseases such as Alzheimer's disease (AD) should be more efficiently tackled by drugs which hit multiple biological targets involved in their pathogenesis. We have recently developed a new family of huprine-tacrine heterodimers, rationally designed to hit multiple targets involved
Koji Hori et al.
Neuropsychobiology, 63(3), 147-153 (2011-01-14)
Alzheimer's disease (AD) is well known as a disease characterized by degeneration of cholinergic neuronal activity in the brain. It follows that patients with AD would be sensitive to an 'anticholinergic burden', and also that medicine with anticholinergic properties would
M A Siddiqui et al.
Toxicology in vitro : an international journal published in association with BIBRA, 22(7), 1681-1688 (2008-08-02)
Effect of 4-hydroxynonenal (HNE), a long-chain alpha, beta unsaturated aldehyde product, generated by the oxidation of omega-6 polyunsaturated fatty acids on the sensitivity of selected neurotransmitter receptors was studied in PC-12 cells. Cytotoxicity profiling was carried out at varying concentrations
Kylie J Mansfield et al.
The Journal of pharmacology and experimental therapeutics, 328(3), 893-899 (2008-11-26)
Recent studies have described muscarinic receptors on the mucosa and the detrusor of the human urinary bladder. Muscarinic receptor antagonists are effective in the treatment of overactive bladder (OAB), but their site(s) of action and actual therapeutic target are unclear.
Barbara C van Munster et al.
Journal of psychiatric research, 46(10), 1339-1345 (2012-08-01)
Delirium, a frequently occurring, devastating disease, is often underdiagnosed, especially in dementia. Serum anticholinergic activity (SAA) was proposed as a disease marker as it may reflect delirium's important pathogenetic mechanism, cholinergic deficiency. We assessed the association of serum anticholinergic activity
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service